Overview

Webcast ImageWebcast
Q3 2017 Audentes Therapeutics Earnings Call (Replay)
11/14/17 at 1:30 p.m. PT
Q3 2017 Audentes Therapeutics Earnings Call
Tuesday, November 14, 2017 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Piper Jaffray Healthcare Conference (Live)
11/28/17 at 11:00 a.m. ET
Piper Jaffray Healthcare Conference
Tuesday, November 28, 2017 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Evercore ISI Biopharma Catalyst/Deep Dive Conference (Live)
11/29/17 at 11:45 a.m. ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Wednesday, November 29, 2017 11:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$27.46
Change (%)0.00 (0.00%)
Volume0
Data as of 11/20/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $27.46 with a 52 week high of $33.43 and a 52 week low of $13.90.
Recent NewsMore >>
11/21/17
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
11/16/17
Audentes Therapeutics to Present at Upcoming Investor Conferences
11/14/17
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Upcoming EventsMore >>
Tuesday, November 28, 2017 11:00 a.m. ET
Piper Jaffray Healthcare Conference

Wednesday, November 29, 2017 11:45 a.m. ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference

Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.